Our Network Imfinzi plus Lynparza reduced the risk of disease progression or death by 45% vs. chemotherapy in advanced or recurrent endometrial cancer Tags: #Research #Oncology #Medical Oncology #Clinical research #AstraZeneca Imfinzi reduced the risk of disease progression or death by 29% vs. chemotherapy. First Phase III trial to demonstrate clinical benefit of immunotherapy plus PARP inhibition in advanced or recurrent endometrial cancer.
